The polypeptide may also include {HEAD ~ additional short sequences} at the beginning and end of the core sequence which are physiologically harmless and do not contribute to the ability of the core sequence to bind compete with {TAIL ~ native IgE} for the high affinity receptor sites on human cells 
The polypeptide may also include { HEAD ~ additional short sequences } at the beginning and end of the core sequence which are physiologically harmless and do not contribute to the ability of the core sequence to bind compete with { TAIL ~ native IgE } for the high affinity receptor sites on human cells
OTH OTH OTH OTH OTH HEAD HEAD HEAD HEAD HEAD HEAD HEAD OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH TAIL TAIL TAIL TAIL TAIL TAIL OTH OTH OTH OTH OTH OTH OTH OTH OTH